

Epilepsia Open 2022 Annual Report

ACTIVITIES

- The Editor in Chief (EiC), Deputy Editor, Managing Editor and Editorial Board, in collaboration with Wiley and the ILAE leadership when needed, have been convening via teleconferences to discuss the progress, strategies and action items and advance the quality and visibility of the journal.
- There were two virtual meetings of the editorial board in 2022 (winter and summer), regular meetings between the EiC and managing editor, occasional zoom meetings of the EiC and the publication council chair and/or Wiley. Further communications via emails were done as needed.
- Face-to-face meetings with the publication council, ILAE journal editors and ILAE leadership occurred in June 2022 (17-18 June 2022, Hoboken, NJ) and during the American Epilepsy Society (AES) meeting (4 December 2022, Nashville, TN)




Figure 1: Special Issue on Redefining The Hypotheses For Drug Resistant Epilepsy, guest edited by Dr. Luisa Rocha

ACCOMPLISHMENTS

First Impact Factor (2021): *Epilepsia Open* received its first impact factor (IF) of 4.026 in 2022 and was ranked at Q2 (90/212) journals in Clinical Neurology.

Submissions:

In 2022, we received a total of 183 original submissions and a total of 343 original plus revised submissions. Transfers from *Epilepsia* are 18% of publications. 77.6% of articles reported clinical and 22.4% basic/translational research.

Peer review, processing times:

- The acceptance rate is 70% for all articles decided within 2022 and 63% among articles submitted within 2022.
- The median time to first decision is 41 days and to final decision is 73 days. The processing time from the time of acceptance, is 2.4 days to online “Accepted article” and 22 days to early view.

Special Issues:

- Special issue on “Redesigning the Hypotheses for Drug-Resistant Epilepsy”, guest edited by Dr. Luisa Rocha, authored by participants of the 3rd Latin-American Workshop on Neurobiology of Epilepsy.

- Special issue on “Status epilepticus” is honoring the legacy of Dr. Claude Wasterlain has been almost completed. Guest editors: David Naylor, Denny Fujikawa, Andrey Mazarati, Raman Sankar.
- Special issue on preclinical common data elements (CDEs) created by the TASK3 working groups of the AES/ILAE Joint Translational Task Force is almost completed. Guest editors: Aristeia Galanopoulou, Matthew Walker, Terence O’Brien, Greg Worrell.

Bibliometrics:

The 2022 downloads were 178,890, until end of November 2022 (Figure 2). In 2022, the average citations per article during the 2 years following publication were 4.8 for original research and 3.69 for reviews (Figure 3).

Indexing: *Epilepsia Open* is fully indexed.




Figure 2: Downloads of *Epilepsia Open* per annum. The estimates of year 2022 downloads are only until the end of November 2022.

Figure 3 A: Top 2022 Downloaded Epilepsia Open articles

Article Title	Publication Year	Full Text Downloads	Author
Barriers to generic antiseizure medication use: Results of a global survey by the International League Against Epilepsy Generic Substitution Task Force	2022	1,802	WELTY, T
Serotonin receptors in epilepsy: Novel treatment targets?	2022	1,577	LAGAE, L
An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: A report from the Fenfluramine European Early Access Program	2022	1,229	GAMMAITONI, A
Factors not considered in the study of drug-resistant epilepsy: Drug-resistant epilepsy: Assessment of neuroinflammation	2022	1,209	CAMPOS-BEDOLLA P
Antiseizure medication discovery: Recent and future paradigm shifts	2022	1,040	TALEVI, A
Dyscalculia and dyslexia in Chinese children with idiopathic epilepsy: Different patterns of prevalence, comorbidity, and gender differences	2022	1,024	CHEN, Q
Glymphatic system dysfunction in temporal lobe epilepsy patients with hippocampal sclerosis	2022	1,015	PARK, K
Long-term open-label peramppanel: Generalized tonic-clonic seizures in idiopathic generalized epilepsy	2022	964	FRENCH, J
Recurrence rates and risk factors for seizure recurrence following antiseizure medication withdrawal in adolescent patients with genetic generalized epilepsy	2022	958	TOHYAMA, J
Interictal pattern on scalp electroencephalogram predicts excellent s	2022	875	SHAO, X

Figure 3 B: Top 2021-2022 Cited Epilepsia Open articles

Article Title	Publication Year	Total Citations	Author
Managing depression and anxiety in people with epilepsy: A survey of epilepsy health professionals by the ILAE Psychology Task Force	2021	17	GANDY, M
Brain-responsive corticothalamic stimulation in the pulvinar nucleus for the treatment of regional neocortical epilepsy: A case series	2021	15	BURDETTE, D
FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force	2021	14	FRENCH, J
Proposal to optimize evaluation and treatment of Febrile infection-related epilepsy syndrome (FIRES): A Report from FIRES workshop	2021	13	KOH, S
The gut microbiome in drug-resistant epilepsy	2021	10	CHATZIKONSTANTINOU, S
Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe	2021	9	LAGAE, L
Why child neurologists talk about SUDEP: Results from two cross-sectional surveys	2021	9	KELLER, A
Addressing neuropsychological diagnostics in adults with epilepsy: Introducing the International Classification of Cognitive Disorders in Epilepsy: The IC CODE Initiative	2021	8	BAXENDALE, S
Antiepileptogenesis and disease modification: Progress, challenges, and the path forward-Report of the Preclinical Working Group of the 2018 NINDS-sponsored antiepileptogenesis and disease modification workshop	2021	7	GALANOPOULOU, A
Impact of the COVID-19 lockdown on patients and families with Dravet syndrome	2021	7	NABOUT, R
Sleep-wake characteristics in a mouse model of severe traumatic brain injury: Relation to posttraumatic epilepsy	2021	6	MAGANTI, R

Figure 3 C: Top 2022 altmetric attention scores in Epilepsia Open articles

Title	Publication Date	Altmetric Attention Score	First author
Impact of COVID-19 pandemic on epilepsy care in Japan: A national level multicenter retrospective cohort study	6/12/22	40	KURODA N
3D figure of epilepsy syndromes	11/10/22	29	NABBOUT R
Barriers to generic antiseizure medication use: Results of a global survey by the International League Against Epilepsy Generic Substitution Task Force	2/18/22	21	NIYONGERE J
Recurrence rates and risk factors for seizure recurrence following antiseizure medication withdrawal in adolescent patients with genetic generalized epilepsy	4/28/22	15	KOMATSUBARA T
Effect of fenfluramine on seizures and comorbidities in SCN8A-developmental and epileptic encephalopathy: A case series	7/20/22	14	ALEDO-SERRANO A
One year cost- effectiveness of callosotomy vs vagus nerve stimulation for drug-resistant seizures in Lennox-Gastaut Syndrome: A decision analytic model	1/17/22	13	ABEL TJ
Insulo-opercular stereoelectroencephalography exploration in children and young adults: Indications, techniques, and safety	10/5/22	11	CHILUKURI AS
Long-term outcomes after NORSE : Treatment with vagus nerve stimulation	10/9/22	10	ESPINO PS
Factors not considered in the study of drug-resistant epilepsy: Drug-resistant epilepsy: Assessment of neuroinflammation	3/16/22	10	CAMPOS-BEDOLLA P
The state of pediatric tuberous sclerosis complex epilepsy care: Results from a national survey	10/5/22	10	WHITNEY R
Optimal timing of interictal FDG PET for epilepsy surgery: A systematic review on time since last seizure	6/20/22	10	DE LAAT NN
Extreme late onset of genetic generalized epilepsy in older adults and the elderly: A cohort study and literature review	11/20/22	10	ALZHRANY M
Medical treatment in infants and young children with epilepsy: Off-label use of antiseizure medications. Survey Report of ILAE Task Force Medical Therapies in Children	11/16/22	10	SOURBRON J

Epilepsia Open Prizes:

- The *Epilepsia Open* Basic Science Prize was awarded to Dr. Morgan Sturgeon (USA).
- The *Epilepsia Open* Clinical Science Prize was awarded to Dr. Barbora Benova (Czech Republic) and Dr. Hanna Mai Hulshof (Netherlands).



Figure 4: 2022 Epilepsia Open Prize awardees

HIGHLIGHTS

- *Epilepsia Open* received its first impact factor (IF) in 2022: 4.026, which is an exceptional achievement attesting to the growth and quality of the journal and the commitment and outstanding work of our editorial board.
- The 2022 *Epilepsia Open* prizes for best research published in 2021 by young investigators were given to Dr. Morgan Sturgeon (USA, Basic Science) and Dr. Barbora Benova (Czech Republic, Clinical Science) and Dr. Hanna Mai Hulshof (Netherlands, Clinical Science).
- A special issue was published in 2022 on “Redesigning the Hypotheses for Drug-Resistant Epilepsy”, guest edited by Dr Luisa Rocha. The collection of critical reviews was based on the 3rd Latin-American Workshop on Neurobiology of Epilepsy “REDISIGNING THE HYPOTHESES FOR DRUG-RESISTANT EPILEPSY” and were authored by prominent Latin American investigators.

MEETINGS

Two virtual editorial board meetings and two meetings with the publication council were organized in 2022.

Report submitted by Aristeia Galanopoulou